TocilizumabV1, PascalFrancis, Curation, bibRecord, 000145

Early effects of IL-6 receptor inhibition on bone homeostasis: a pilot study in women with rheumatoid arthritis

Identifieur interne : 000145 ( PascalFrancis/Curation ); précédent : 000144; suivant : 000146

Early effects of IL-6 receptor inhibition on bone homeostasis: a pilot study in women with rheumatoid arthritis

Auteurs : E. Terpos [Grèce] ; K. Fragiadaki [Grèce] ; M. Konsta [Grèce] ; C. Bratengeier [Autriche] ; A. Papatheodorou [Grèce] ; P. P. Sfikakis [Grèce]

Source :

Clinical and experimental rheumatology : (Testo stampato) [ 0392-856X ] ; 2011.

RBID : Pascal:12-0100652

Descripteurs français

Pascal (Inist)
- Polyarthrite rhumatoïde, Tocilizumab, Interleukine 6, Os, Homéostasie, Femme, Ligand RANKL, Rhumatologie, Chronique, Immunomodulateur, Immunodépresseur.
Wicri :
- topic : Femme.

English descriptors

KwdEn :
- Bone, Chronic, Homeostasis, Immunomodulator, Immunosuppressive agent, Interleukin 6, Receptor activator Nfkb ligand, Rheumatoid arthritis, Rheumatology, Tocilizumab, Woman.

Abstract

Objective A critical role of interleukin-6 (IL-6) in bone homeostasis has been suggested in experimental studies. We examined whether inhibition of IL-6 receptor in patients with rheumatoid arthritis (RA) results in early alterations of circulating markers of bone remodelling. Methods Circulating levels of osteoprotegerin, receptor activator of nuclear factor-kappaB ligand (RANKL), Wnt signalling pathway inhibitors Dickkopf-1 (Dkk-1) and sclerostin, markers of bone resorption (C-terminal cross-linking telopeptide of collagen type-I (CTX), tartrate-resistant acid phosphatase isoform-5b) and bone formation (bone-specific alkaline-phosphatase, osteocalcin) were examined in 22 women with active RA before and after two monthly infusions of tocilizumab (8mg/kg each); 'healthy', non-osteopenic, 1:1 age-matched women served as controls. Results At baseline, osteoprotegerin/RANKL ratio in patients was lower than controls by 5-fold; circulating osteoprotegerin correlated negatively with corresponding 28-joint-count disease activity scores and circulating RANKL correlated positively with C-reactive protein. Also, Dkk-1, sclerostin, CTX and osteocalcin levels were higher in RA than controls. After two months, osteoprotegerin/RANKL ratio increased, Dkk-1 decreased and sclerostin increased comparing to baseline; other markers did not change significantly. Increases of osteoprotegerin/RANKL ratio were more prominent in 10 patients who achieved remission or low disease activity after tocilizumab than in 12 patients who did not. In contrast, the significant alterations of both Wnt inhibitors were comparable between these patient subgroups. Conclusions Anti-IL-6 therapy induced suppression of the inflammatory response affects rapidly the disrupted bone homeostasis in active RA. An additional, possibly specific, effect of IL-6 receptor inhibition on bone remodelling in humans should be further examined.

A01	`01`	`1`		`@0 0392-856X`
A03		`1`		`@0 Clin. exp. rheumatol. : Testo stamp.)`
A05				`@2 29`
A06				`@2 6`
A08	`01`	`1`	`ENG`	`@1 Early effects of IL-6 receptor inhibition on bone homeostasis: a pilot study in women with rheumatoid arthritis`
A11	`01`	`1`		`@1 TERPOS (E.)`
A11	`02`	`1`		`@1 FRAGIADAKI (K.)`
A11	`03`	`1`		`@1 KONSTA (M.)`
A11	`04`	`1`		`@1 BRATENGEIER (C.)`
A11	`05`	`1`		`@1 PAPATHEODOROU (A.)`
A11	`06`	`1`		`@1 SFIKAKIS (P. P.)`
A14	`01`			`@1 First Department of Propedeutic and Internal Medicine, Laikon Hospital @3 GRC @Z 1 aut. @Z 2 aut. @Z 3 aut. @Z 6 aut.`
A14	`02`			`@1 Department of Clinical Therapeutics, Alexandra Hospital, Athens University Medical School @3 GRC @Z 1 aut. @Z 5 aut.`
A14	`03`			`@1 Biomarker Design Forschungs GmbH @2 Vienna @3 AUT @Z 4 aut.`
A20				`@1 921-925`
A21				`@1 2011`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20920 @5 354000508880810040`
A44				`@0 0000 @1 © 2012 INIST-CNRS. All rights reserved.`
A45				`@0 17 ref.`
A47	`01`	`1`		`@0 12-0100652`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Clinical and experimental rheumatology : (Testo stampato)`
A66	`01`			`@0 ITA`
C01	`01`		`ENG`	@0 Objective A critical role of interleukin-6 (IL-6) in bone homeostasis has been suggested in experimental studies. We examined whether inhibition of IL-6 receptor in patients with rheumatoid arthritis (RA) results in early alterations of circulating markers of bone remodelling. Methods Circulating levels of osteoprotegerin, receptor activator of nuclear factor-kappaB ligand (RANKL), Wnt signalling pathway inhibitors Dickkopf-1 (Dkk-1) and sclerostin, markers of bone resorption (C-terminal cross-linking telopeptide of collagen type-I (CTX), tartrate-resistant acid phosphatase isoform-5b) and bone formation (bone-specific alkaline-phosphatase, osteocalcin) were examined in 22 women with active RA before and after two monthly infusions of tocilizumab (8mg/kg each); 'healthy', non-osteopenic, 1:1 age-matched women served as controls. Results At baseline, osteoprotegerin/RANKL ratio in patients was lower than controls by 5-fold; circulating osteoprotegerin correlated negatively with corresponding 28-joint-count disease activity scores and circulating RANKL correlated positively with C-reactive protein. Also, Dkk-1, sclerostin, CTX and osteocalcin levels were higher in RA than controls. After two months, osteoprotegerin/RANKL ratio increased, Dkk-1 decreased and sclerostin increased comparing to baseline; other markers did not change significantly. Increases of osteoprotegerin/RANKL ratio were more prominent in 10 patients who achieved remission or low disease activity after tocilizumab than in 12 patients who did not. In contrast, the significant alterations of both Wnt inhibitors were comparable between these patient subgroups. Conclusions Anti-IL-6 therapy induced suppression of the inflammatory response affects rapidly the disrupted bone homeostasis in active RA. An additional, possibly specific, effect of IL-6 receptor inhibition on bone remodelling in humans should be further examined.
C02	`01`	`X`		`@0 002B15D`
C02	`02`	`X`		`@0 002B02Q`
C03	`01`	`X`	`FRE`	`@0 Polyarthrite rhumatoïde @5 01`
C03	`01`	`X`	`ENG`	`@0 Rheumatoid arthritis @5 01`
C03	`01`	`X`	`SPA`	`@0 Poliartritis reumatoidea @5 01`
C03	`02`	`X`	`FRE`	`@0 Tocilizumab @2 FR @5 04`
C03	`02`	`X`	`ENG`	`@0 Tocilizumab @2 FR @5 04`
C03	`02`	`X`	`SPA`	`@0 Tocilizumab @2 FR @5 04`
C03	`03`	`X`	`FRE`	`@0 Interleukine 6 @5 07`
C03	`03`	`X`	`ENG`	`@0 Interleukin 6 @5 07`
C03	`03`	`X`	`SPA`	`@0 Interleuquina 6 @5 07`
C03	`04`	`X`	`FRE`	`@0 Os @5 08`
C03	`04`	`X`	`ENG`	`@0 Bone @5 08`
C03	`04`	`X`	`SPA`	`@0 Hueso @5 08`
C03	`05`	`X`	`FRE`	`@0 Homéostasie @5 09`
C03	`05`	`X`	`ENG`	`@0 Homeostasis @5 09`
C03	`05`	`X`	`SPA`	`@0 Homeostasis @5 09`
C03	`06`	`X`	`FRE`	`@0 Femme @5 13`
C03	`06`	`X`	`ENG`	`@0 Woman @5 13`
C03	`06`	`X`	`SPA`	`@0 Mujer @5 13`
C03	`07`	`X`	`FRE`	`@0 Ligand RANKL @5 15`
C03	`07`	`X`	`ENG`	`@0 Receptor activator Nfkb ligand @5 15`
C03	`07`	`X`	`SPA`	`@0 Ligando RANKL @5 15`
C03	`08`	`X`	`FRE`	`@0 Rhumatologie @5 16`
C03	`08`	`X`	`ENG`	`@0 Rheumatology @5 16`
C03	`08`	`X`	`SPA`	`@0 Reumatología @5 16`
C03	`09`	`X`	`FRE`	`@0 Chronique @5 30`
C03	`09`	`X`	`ENG`	`@0 Chronic @5 30`
C03	`09`	`X`	`SPA`	`@0 Crónico @5 30`
C03	`10`	`X`	`FRE`	`@0 Immunomodulateur @5 31`
C03	`10`	`X`	`ENG`	`@0 Immunomodulator @5 31`
C03	`10`	`X`	`SPA`	`@0 Inmunomodulador @5 31`
C03	`11`	`X`	`FRE`	`@0 Immunodépresseur @5 32`
C03	`11`	`X`	`ENG`	`@0 Immunosuppressive agent @5 32`
C03	`11`	`X`	`SPA`	`@0 Inmunodepresor @5 32`
C07	`01`	`X`	`FRE`	`@0 Homme`
C07	`01`	`X`	`ENG`	`@0 Human`
C07	`01`	`X`	`SPA`	`@0 Hombre`
C07	`02`	`X`	`FRE`	`@0 Maladie autoimmune @5 37`
C07	`02`	`X`	`ENG`	`@0 Autoimmune disease @5 37`
C07	`02`	`X`	`SPA`	`@0 Enfermedad autoinmune @5 37`
C07	`03`	`X`	`FRE`	`@0 Rhumatisme inflammatoire @5 38`
C07	`03`	`X`	`ENG`	`@0 Inflammatory joint disease @5 38`
C07	`03`	`X`	`SPA`	`@0 Reumatismo inflamatorio @5 38`
C07	`04`	`X`	`FRE`	`@0 Pathologie du système ostéoarticulaire @5 39`
C07	`04`	`X`	`ENG`	`@0 Diseases of the osteoarticular system @5 39`
C07	`04`	`X`	`SPA`	`@0 Sistema osteoarticular patología @5 39`
C07	`05`	`X`	`FRE`	`@0 Immunopathologie @5 40`
C07	`05`	`X`	`ENG`	`@0 Immunopathology @5 40`
C07	`05`	`X`	`SPA`	`@0 Inmunopatología @5 40`
N21				`@1 079`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000119

Links to Exploration step

Pascal:12-0100652

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Early effects of IL-6 receptor inhibition on bone homeostasis: a pilot study in women with rheumatoid arthritis</title>
<author><name sortKey="Terpos, E" sort="Terpos, E" uniqKey="Terpos E" first="E." last="Terpos">E. Terpos</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>First Department of Propedeutic and Internal Medicine, Laikon Hospital</s1>
<s3>GRC</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Grèce</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Clinical Therapeutics, Alexandra Hospital, Athens University Medical School</s1>
<s3>GRC</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Grèce</country>
</affiliation>
</author>
<author><name sortKey="Fragiadaki, K" sort="Fragiadaki, K" uniqKey="Fragiadaki K" first="K." last="Fragiadaki">K. Fragiadaki</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>First Department of Propedeutic and Internal Medicine, Laikon Hospital</s1>
<s3>GRC</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Grèce</country>
</affiliation>
</author>
<author><name sortKey="Konsta, M" sort="Konsta, M" uniqKey="Konsta M" first="M." last="Konsta">M. Konsta</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>First Department of Propedeutic and Internal Medicine, Laikon Hospital</s1>
<s3>GRC</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Grèce</country>
</affiliation>
</author>
<author><name sortKey="Bratengeier, C" sort="Bratengeier, C" uniqKey="Bratengeier C" first="C." last="Bratengeier">C. Bratengeier</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Biomarker Design Forschungs GmbH</s1>
<s2>Vienna</s2>
<s3>AUT</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Autriche</country>
</affiliation>
</author>
<author><name sortKey="Papatheodorou, A" sort="Papatheodorou, A" uniqKey="Papatheodorou A" first="A." last="Papatheodorou">A. Papatheodorou</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Clinical Therapeutics, Alexandra Hospital, Athens University Medical School</s1>
<s3>GRC</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Grèce</country>
</affiliation>
</author>
<author><name sortKey="Sfikakis, P P" sort="Sfikakis, P P" uniqKey="Sfikakis P" first="P. P." last="Sfikakis">P. P. Sfikakis</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>First Department of Propedeutic and Internal Medicine, Laikon Hospital</s1>
<s3>GRC</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Grèce</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">12-0100652</idno>
<date when="2011">2011</date>
<idno type="stanalyst">PASCAL 12-0100652 INIST</idno>
<idno type="RBID">Pascal:12-0100652</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000119</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000145</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Early effects of IL-6 receptor inhibition on bone homeostasis: a pilot study in women with rheumatoid arthritis</title>
<author><name sortKey="Terpos, E" sort="Terpos, E" uniqKey="Terpos E" first="E." last="Terpos">E. Terpos</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>First Department of Propedeutic and Internal Medicine, Laikon Hospital</s1>
<s3>GRC</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Grèce</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Clinical Therapeutics, Alexandra Hospital, Athens University Medical School</s1>
<s3>GRC</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Grèce</country>
</affiliation>
</author>
<author><name sortKey="Fragiadaki, K" sort="Fragiadaki, K" uniqKey="Fragiadaki K" first="K." last="Fragiadaki">K. Fragiadaki</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>First Department of Propedeutic and Internal Medicine, Laikon Hospital</s1>
<s3>GRC</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Grèce</country>
</affiliation>
</author>
<author><name sortKey="Konsta, M" sort="Konsta, M" uniqKey="Konsta M" first="M." last="Konsta">M. Konsta</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>First Department of Propedeutic and Internal Medicine, Laikon Hospital</s1>
<s3>GRC</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Grèce</country>
</affiliation>
</author>
<author><name sortKey="Bratengeier, C" sort="Bratengeier, C" uniqKey="Bratengeier C" first="C." last="Bratengeier">C. Bratengeier</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Biomarker Design Forschungs GmbH</s1>
<s2>Vienna</s2>
<s3>AUT</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Autriche</country>
</affiliation>
</author>
<author><name sortKey="Papatheodorou, A" sort="Papatheodorou, A" uniqKey="Papatheodorou A" first="A." last="Papatheodorou">A. Papatheodorou</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Clinical Therapeutics, Alexandra Hospital, Athens University Medical School</s1>
<s3>GRC</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Grèce</country>
</affiliation>
</author>
<author><name sortKey="Sfikakis, P P" sort="Sfikakis, P P" uniqKey="Sfikakis P" first="P. P." last="Sfikakis">P. P. Sfikakis</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>First Department of Propedeutic and Internal Medicine, Laikon Hospital</s1>
<s3>GRC</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Grèce</country>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Clinical and experimental rheumatology : (Testo stampato)</title>
<title level="j" type="abbreviated">Clin. exp. rheumatol. : Testo stamp.)</title>
<idno type="ISSN">0392-856X</idno>
<imprint><date when="2011">2011</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Clinical and experimental rheumatology : (Testo stampato)</title>
<title level="j" type="abbreviated">Clin. exp. rheumatol. : Testo stamp.)</title>
<idno type="ISSN">0392-856X</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Bone</term>
<term>Chronic</term>
<term>Homeostasis</term>
<term>Immunomodulator</term>
<term>Immunosuppressive agent</term>
<term>Interleukin 6</term>
<term>Receptor activator Nfkb ligand</term>
<term>Rheumatoid arthritis</term>
<term>Rheumatology</term>
<term>Tocilizumab</term>
<term>Woman</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Polyarthrite rhumatoïde</term>
<term>Tocilizumab</term>
<term>Interleukine 6</term>
<term>Os</term>
<term>Homéostasie</term>
<term>Femme</term>
<term>Ligand RANKL</term>
<term>Rhumatologie</term>
<term>Chronique</term>
<term>Immunomodulateur</term>
<term>Immunodépresseur</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Femme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Objective A critical role of interleukin-6 (IL-6) in bone homeostasis has been suggested in experimental studies. We examined whether inhibition of IL-6 receptor in patients with rheumatoid arthritis (RA) results in early alterations of circulating markers of bone remodelling. Methods Circulating levels of osteoprotegerin, receptor activator of nuclear factor-kappaB ligand (RANKL), Wnt signalling pathway inhibitors Dickkopf-1 (Dkk-1) and sclerostin, markers of bone resorption (C-terminal cross-linking telopeptide of collagen type-I (CTX), tartrate-resistant acid phosphatase isoform-5b) and bone formation (bone-specific alkaline-phosphatase, osteocalcin) were examined in 22 women with active RA before and after two monthly infusions of tocilizumab (8mg/kg each); 'healthy', non-osteopenic, 1:1 age-matched women served as controls. Results At baseline, osteoprotegerin/RANKL ratio in patients was lower than controls by 5-fold; circulating osteoprotegerin correlated negatively with corresponding 28-joint-count disease activity scores and circulating RANKL correlated positively with C-reactive protein. Also, Dkk-1, sclerostin, CTX and osteocalcin levels were higher in RA than controls. After two months, osteoprotegerin/RANKL ratio increased, Dkk-1 decreased and sclerostin increased comparing to baseline; other markers did not change significantly. Increases of osteoprotegerin/RANKL ratio were more prominent in 10 patients who achieved remission or low disease activity after tocilizumab than in 12 patients who did not. In contrast, the significant alterations of both Wnt inhibitors were comparable between these patient subgroups. Conclusions Anti-IL-6 therapy induced suppression of the inflammatory response affects rapidly the disrupted bone homeostasis in active RA. An additional, possibly specific, effect of IL-6 receptor inhibition on bone remodelling in humans should be further examined.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0392-856X</s0>
</fA01>
<fA03 i2="1"><s0>Clin. exp. rheumatol. : Testo stamp.)</s0>
</fA03>
<fA05><s2>29</s2>
</fA05>
<fA06><s2>6</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Early effects of IL-6 receptor inhibition on bone homeostasis: a pilot study in women with rheumatoid arthritis</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>TERPOS (E.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>FRAGIADAKI (K.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>KONSTA (M.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>BRATENGEIER (C.)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>PAPATHEODOROU (A.)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>SFIKAKIS (P. P.)</s1>
</fA11>
<fA14 i1="01"><s1>First Department of Propedeutic and Internal Medicine, Laikon Hospital</s1>
<s3>GRC</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Department of Clinical Therapeutics, Alexandra Hospital, Athens University Medical School</s1>
<s3>GRC</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Biomarker Design Forschungs GmbH</s1>
<s2>Vienna</s2>
<s3>AUT</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA20><s1>921-925</s1>
</fA20>
<fA21><s1>2011</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20920</s2>
<s5>354000508880810040</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2012 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>17 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>12-0100652</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Clinical and experimental rheumatology : (Testo stampato)</s0>
</fA64>
<fA66 i1="01"><s0>ITA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Objective A critical role of interleukin-6 (IL-6) in bone homeostasis has been suggested in experimental studies. We examined whether inhibition of IL-6 receptor in patients with rheumatoid arthritis (RA) results in early alterations of circulating markers of bone remodelling. Methods Circulating levels of osteoprotegerin, receptor activator of nuclear factor-kappaB ligand (RANKL), Wnt signalling pathway inhibitors Dickkopf-1 (Dkk-1) and sclerostin, markers of bone resorption (C-terminal cross-linking telopeptide of collagen type-I (CTX), tartrate-resistant acid phosphatase isoform-5b) and bone formation (bone-specific alkaline-phosphatase, osteocalcin) were examined in 22 women with active RA before and after two monthly infusions of tocilizumab (8mg/kg each); 'healthy', non-osteopenic, 1:1 age-matched women served as controls. Results At baseline, osteoprotegerin/RANKL ratio in patients was lower than controls by 5-fold; circulating osteoprotegerin correlated negatively with corresponding 28-joint-count disease activity scores and circulating RANKL correlated positively with C-reactive protein. Also, Dkk-1, sclerostin, CTX and osteocalcin levels were higher in RA than controls. After two months, osteoprotegerin/RANKL ratio increased, Dkk-1 decreased and sclerostin increased comparing to baseline; other markers did not change significantly. Increases of osteoprotegerin/RANKL ratio were more prominent in 10 patients who achieved remission or low disease activity after tocilizumab than in 12 patients who did not. In contrast, the significant alterations of both Wnt inhibitors were comparable between these patient subgroups. Conclusions Anti-IL-6 therapy induced suppression of the inflammatory response affects rapidly the disrupted bone homeostasis in active RA. An additional, possibly specific, effect of IL-6 receptor inhibition on bone remodelling in humans should be further examined.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B15D</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B02Q</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Polyarthrite rhumatoïde</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Rheumatoid arthritis</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Poliartritis reumatoidea</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Tocilizumab</s0>
<s2>FR</s2>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Tocilizumab</s0>
<s2>FR</s2>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Tocilizumab</s0>
<s2>FR</s2>
<s5>04</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Interleukine 6</s0>
<s5>07</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Interleukin 6</s0>
<s5>07</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Interleuquina 6</s0>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Os</s0>
<s5>08</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Bone</s0>
<s5>08</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Hueso</s0>
<s5>08</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Homéostasie</s0>
<s5>09</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Homeostasis</s0>
<s5>09</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Homeostasis</s0>
<s5>09</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Femme</s0>
<s5>13</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Woman</s0>
<s5>13</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Mujer</s0>
<s5>13</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Ligand RANKL</s0>
<s5>15</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Receptor activator Nfkb ligand</s0>
<s5>15</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Ligando RANKL</s0>
<s5>15</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Rhumatologie</s0>
<s5>16</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Rheumatology</s0>
<s5>16</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Reumatología</s0>
<s5>16</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Chronique</s0>
<s5>30</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Chronic</s0>
<s5>30</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Crónico</s0>
<s5>30</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Immunomodulateur</s0>
<s5>31</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Immunomodulator</s0>
<s5>31</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Inmunomodulador</s0>
<s5>31</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Immunodépresseur</s0>
<s5>32</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Immunosuppressive agent</s0>
<s5>32</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Inmunodepresor</s0>
<s5>32</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Homme</s0>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Human</s0>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Hombre</s0>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Maladie autoimmune</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Autoimmune disease</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Enfermedad autoinmune</s0>
<s5>37</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Rhumatisme inflammatoire</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Inflammatory joint disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Reumatismo inflamatorio</s0>
<s5>38</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Pathologie du système ostéoarticulaire</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Diseases of the osteoarticular system</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Sistema osteoarticular patología</s0>
<s5>39</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Immunopathologie</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Immunopathology</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Inmunopatología</s0>
<s5>40</s5>
</fC07>
<fN21><s1>079</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/PascalFrancis/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000145 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 000145 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:12-0100652
   |texte=   Early effects of IL-6 receptor inhibition on bone homeostasis: a pilot study in women with rheumatoid arthritis
}}

This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021

	Serveur d'exploration Tocilizumab
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration Tocilizumab

Early effects of IL-6 receptor inhibition on bone homeostasis: a pilot study in women with rheumatoid arthritis

Early effects of IL-6 receptor inhibition on bone homeostasis: a pilot study in women with rheumatoid arthritis

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri